Potential central nervous system antitumor agents. Hydantoin derivatives
- PMID: 1159704
- DOI: 10.1021/jm00242a019
Potential central nervous system antitumor agents. Hydantoin derivatives
Abstract
Hydantoin derivatives of varying lipophilic character were prepared as nitrogen mustard carriers for CNS antitumor evaluation. Activity was studied in the murine ependymoblastoma brain tumor system. Multiple cures were observed for three of the four analogs examined. The compounds were also active in the intraperitoneal leukemia L1210 and P388 systems as well as in B16 melanoma and Lewis lung carcinoma.
Similar articles
-
Spiromustine: a new agent entering clinical trials.Invest New Drugs. 1983;1(4):303-8. doi: 10.1007/BF00177413. Invest New Drugs. 1983. PMID: 6381379 Review.
-
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.J Med Chem. 1976 Feb;19(2):313-7. doi: 10.1021/jm00224a022. J Med Chem. 1976. PMID: 1249812
-
Potential CNS antitumor agents--phenothiazines I: Nitrogen mustard derivatives.J Pharm Sci. 1976 Nov;65(11):1699-701. doi: 10.1002/jps.2600651136. J Pharm Sci. 1976. PMID: 994007
-
Potential central nervous system antitumor agents. Aziridinylbenzoquinones.J Med Chem. 1976 Nov;19(11):1302-8. doi: 10.1021/jm00233a010. J Med Chem. 1976. PMID: 1003407
-
Conjugated system of homo-aza-steroidal esters in cancer chemotherapy.Anticancer Res. 1994 Nov-Dec;14(6B):2525-8. Anticancer Res. 1994. PMID: 7872677 Review.
Cited by
-
New agents in the treatment of primary brain tumors.J Neurooncol. 1994;20(2):141-53. doi: 10.1007/BF01052724. J Neurooncol. 1994. PMID: 7807191 Review.
-
Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.Invest New Drugs. 1985;3(4):331-4. doi: 10.1007/BF00170754. Invest New Drugs. 1985. PMID: 2417984
-
Recent Development in Hydantoins, Thiohydantoins, and Selenohydantoins as Anticancer Agents: Structure-activity Relationship and Design Strategies.Mini Rev Med Chem. 2025;25(9):693-726. doi: 10.2174/0113895575329643241206101210. Mini Rev Med Chem. 2025. PMID: 39810539 Review.
-
Spiromustine: a new agent entering clinical trials.Invest New Drugs. 1983;1(4):303-8. doi: 10.1007/BF00177413. Invest New Drugs. 1983. PMID: 6381379 Review.
-
Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.J Neurooncol. 1987;4(3):195-207. doi: 10.1007/BF00150611. J Neurooncol. 1987. PMID: 3104548
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources